258 related articles for article (PubMed ID: 27687312)
1. PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
[No Abstract] [Full Text] [Related]
2. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
Helleday T
Ann Oncol; 2016 May; 27(5):755-7. PubMed ID: 26865580
[No Abstract] [Full Text] [Related]
3. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
4. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
Saillant A; Flippot R
Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
[No Abstract] [Full Text] [Related]
5. Stratifying prostate patients for olaparib.
Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
[TBL] [Abstract][Full Text] [Related]
6. Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
Romero-Laorden N; Piñeiro-Yañez E; Gutierrez-Pecharroman A; Pacheco MI; Calvo E; Al-Shahrour F; Castro E; Olmos D
Ann Oncol; 2017 May; 28(5):1158-1159. PubMed ID: 28453706
[No Abstract] [Full Text] [Related]
7. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
8. Olaparib Targets Some Advanced Prostate Cancers.
Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
[TBL] [Abstract][Full Text] [Related]
9. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
10. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
12. Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
Schweizer MT; Cheng HH; Nelson PS; Montgomery RB
J Clin Oncol; 2020 Nov; 38(32):3740-3742. PubMed ID: 32897829
[No Abstract] [Full Text] [Related]
13. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
14. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
Kwon DH; Booth CM; Prasad V
Eur Urol; 2021 Jun; 79(6):710-712. PubMed ID: 33722420
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Sandhu SK; Omlin A; Hylands L; Miranda S; Barber LJ; Riisnaes R; Reid AH; Attard G; Chen L; Kozarewa I; Gevensleben H; Campbell J; Fenwick K; Assiotis I; Olmos D; Yap TA; Fong P; Tunariu N; Koh D; Molife LR; Kaye S; Lord CJ; Ashworth A; de Bono J
Ann Oncol; 2013 May; 24(5):1416-8. PubMed ID: 23524863
[No Abstract] [Full Text] [Related]
16. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
Saleh N; Copur MS
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365755
[No Abstract] [Full Text] [Related]
17. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
Gornstein EL; Sandefur S; Chung JH; Gay LM; Holmes O; Erlich RL; Soman S; Martin LK; Rose AV; Stephens PJ; Ross JS; Miller VA; Ali SM; Blau S
Clin Breast Cancer; 2018 Apr; 18(2):184-188. PubMed ID: 29325860
[No Abstract] [Full Text] [Related]
18. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
19. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Simmons AD; Nguyen M; Pintus E
BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
[TBL] [Abstract][Full Text] [Related]
20. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]